,PageNo,Text
0,page_1,"['NCT03915860', 'GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 1 of 88', 'CLINICAL TRIAL PROTOCOL', 'PROTOCOL NUMBER: RD.06.SPR.118295', 'CONFIDENTIAL', 'This document contains confidential, proprietary information', 'All the information provided to the Investigator and his/her staff and all data obtained through this', 'GALDERMA clinical trial protocol are confidential. The Sponsor reserves all proprietary rights.', 'No information may be disclosed to any third party without prior written consent from', 'GALDERMA.']"
1,page_2,"['GALDERMA R&D', 'RD.06.SPR.11829. Protocol V02 04Jun2019', 'Page 2 of 88', 'TITLE PAGE', 'Title', 'A Multi-Center Study to evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g cream in the', 'treatment of moderate facial and truncal acne vulgaris', 'Project Name or CD number:', 'Project Number:', 'Clinical Trial Phase:', 'CD5789', '02232', 'Illb', 'IND Number 111091', 'SPONSOR:', 'Name:', 'GALDERMA RESEARCH & DEVELOPMENT, LLC', 'Address:', '14501 North Freeway', 'Fort Worth, TX 76177', 'Telephone:', '(817) 961-5000', 'For any safety questions, please contact the Clinical Safety Officer (CSO) using the contact', 'details provided in Section 7.2.2.2.2.', 'For any medical questions related to the clinical trial protocol, please contact the Medical Expert', 'using the contact details below:', 'Name and Title:', 'PPD', 'MD, Medical Expert', 'Address:', 'Galderma R&D, LLC', '14501 North Freeway', 'Fort Worth, TX 76177', 'USA', 'Telephone (mobile):', 'PPD', 'Fax:', 'PPD', 'E-mail:', 'PPD']"
2,page_3,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 3 of 88', 'This clinical trial will be performed in compliance with applicable regulatory requirements and', 'Good Clinical Practice (GCP). This clinical trial protocol follows guidelines outlined by the', 'International Conference on Harmonisation (ICH) and the Galderma template.']"
3,page_4,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 4 of 88', 'Table of Contents', 'TITLE PAGE', '2', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '16', '1', 'BACKGROUND AND RATIONALE', '18', '1.1', 'Medical background and short rationale for the clinical trial', '18', '1.2', 'Drug profile', '19', '1.3', 'Risk/benefit assessment', '19', '2', 'CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS', '20', '2.1', 'Clinical trial objectives', '20', '2.2', 'Clinical hypotheses', '20', '3', 'OVERALL CLINICAL TRIAL DESCRIPTION', '21', '3.1', 'Efficacy assessment', '21', '3.2', 'Safety Assessment', '21', '3.3', 'Application areas', '21', '4', 'CLINICAL TRIAL DURATION AND TERMINATION', '23', '5', 'SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION', '23', '5.1', 'Number of subjects', '23', '5.2', 'Clinical trial population characteristics', '23', '5.3', 'Inclusion criteria', '23', '5.4', 'Exclusion criteria', '25', '5.5', 'Previous and concomitant therapies', '28', '5.5.1', 'Definition', '28', '5.5.2', 'Categories', '28', '5.5.3', 'Recording', '28', '5.5.4', 'Authorized concomitant therapies', '29', '5.5.5', 'Prohibited concomitant therapies', '29', '5.6', 'Procedures/reasons for subject discontinuation', '30', '6', 'CLINICAL SUPPLIES', '32', '6.1', 'Clinical supply identification and use', '32']"
4,page_5,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 5 of 88', '6.1.1', 'Study drug description', '32', '6.1.2', 'Subject identification number', '33', '6.1.3', 'Kit number', '33', '6.1.4', 'Instructions for use and application', '33', '6.1.5', 'Other supplies', '34', '6.2', 'Study drug packaging and labeling', '35', '6.3', 'Supplies management', '35', '6.3.1', 'Accountability', '35', '6.3.2', 'Storage of clinical study drug', '35', '6.3.3', 'Dispensing and return', '36', '6.3.4', 'Treatment compliance management and record', '36', '6.4', 'Dose modification', '37', '7', 'CLINICAL TRIAL ASSESSMENT', '37', '7.1', 'Efficacy assessments', '37', '7.1.1', 'Efficacy measurements', '37', '7.1.2', 'Efficacy endpoints', '40', '7.2', 'Safety assessment', '41', '7.2.1', 'Local tolerability assessment (of face and of trunk)', '41', '7.2.2', 'Adverse events', '42', '7.3', 'Other assessments', '51', '7.3.1', 'Photographs', '51', '7.3.2', ""Dermatology Life Quality Index (DLQI) / Children's Dermatology Life"", 'Quality Index (C-DLQI)', '52', '7.3.3', 'CompAQ for Facial and Truncal Acne', '53', '7.3.4', 'EuroQoL 5-Dimension (EQ-5D-5L)', '54', '7.3.5', 'Subject satisfaction questionnaire', '54', '7.3.6', 'Study drug acceptability questionnaire', '54', '8', 'CLINICAL TRIAL VISITS DESCRIPTIONS AND PROCEDURES', '54', '8.1', 'Description of clinical trial visits', '54']"
5,page_6,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 6 of 88', '8.1.1', 'Screening visit', '54', '8.1.2', 'Screening/Baseline visit', '55', 'CCI', '8.1.9', 'Unscheduled visits', '61', '8.2', 'Subject instructions (other than study drug administration)', '61', '9', 'STATISTICAL METHODS PLANNED', '62', '9.1', 'Statistical analysis plan', '62', '9.1.1', 'Data transformations', '62', '9.1.2', 'Populations analyzed, evaluability and limitation / evaluation of bias', '63', '9.1.3', 'Data presentation and graphics', '63', '9.2', 'Sample size determination', '65', '10', 'TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE', '65', '10.1', 'Personnel training', '65', '10.2', 'Clinical monitoring', '65', '10.3', 'Data management', '66', '10.4', 'Quality assurance / audit / inspection', '66', '10.5', 'Changes in clinical trial conduct / amendments', '66', '10.5.1', 'Clinical trial conduct', '67', '10.5.2', 'Amendments', '67', '10.5.3', 'Attrition', '67', '11', 'ETHICS AND GENERAL CLINICAL TRIAL CONDUCT CONSIDERATIONS', '67', '11.1', 'Institutional Review Board or Independent Ethics Committee', '68', '11.2', 'Ethical conduct of the clinical trial', '68', '11.3', 'Subject information and consent', '68']"
6,page_7,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 7 of 88', '11.4', 'Contractual requirements', '68', '11.5', 'Data collection and archiving', '68', '11.5.1', 'Data collection', '68', '11.5.2', 'Source documentation', '69', '11.5.3', 'Archives', '69', '11.6', 'Insurance', '69', '12', 'LITERATURE REFERENCE LIST', '69', '13', 'APPENDICES', '72', '13.1', 'Subject Satisfaction Questionnaire', '72', '13.2', 'Study Drug Acceptability Questionnaire', '74', '13.3', 'Dermatology Life Quality Index (DLQITM)', '75', '13.4', ""Children's Dermatology Life Quality Index (C-DLQITM)"", '77', '13.5', 'QOL Questionnaire for Face and Trunk Acne (16 years of age and older)', '79', '13.6', 'EuroQoL 5-Dimension (EQ-5D-5L)', '81', '13.7', 'Fitzpatrick Skin Classification', '83', '13.8', 'Acne Harmonization Lesion Count', '84', 'CCI', '13.10', 'Atrophic Acne Scar Counts', '87', 'Protocol Signature Page', '88']"
7,page_8,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 8 of 88', 'List of Tables', 'Table 1', 'Clinical trial schematic', '13', 'Table 2', 'Schedule of assessments', '14', 'Table 3', 'Exit Form reasons for discontinuation', '31', 'Table 4', 'Description and usage of the study drug', '32', 'Table 5', 'Suspected sensitization - reaction grading', '49', 'Table 6', 'Suspected sensitization - conclusion', '49']"
8,page_9,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 9 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Short Title: Subject Reported Outcomes with use of Trifarotene 50 g/g Cream in Subjects with Moderate Facial', 'and Truncal Acne Vulgaris', 'Lay Title: Studying the Effects of 50g/g Cream on Subjects who have Acne', 'Clinical Trial phase:', 'IIIb', 'Clinical Trial Population:', 'Subjects with moderate acne vulgaris with facial and truncal acne involvement', 'Clinical Trial objectives:', 'The purpose of this study is to evaluate subject reported outcomes with Trifarotene', 'cream.', 'Clinical Trial design:', 'Multi-center, open label, single arm study of Trifarotene cream applied once daily in', 'the evening for 24 weeks.', 'Total number of subjects', 'Approximately 50 subjects will be enrolled in order to obtain 40 subjects at', '(Planned):', 'completion.', 'Number of clinical trial', 'centers (Planned):', 'Region(s) / country(ies)', 'United States', 'involved (Planned):', 'Clinical trial duration:', 'Duration of subject', 'Clinical trial participation for each subject is approximately 24 weeks of study', 'participation:', 'treatment +3 days.', 'Note: Subjects, upon study completion/early termination, will return to standard of', 'care with their physician.', 'Key inclusion criteria', '1.', 'Male or female, 9 years of age and older, at the Screening visit.', '2.', 'The Subject has a facial acne', 'CCI', 'Key exclusion criteria', '1.', 'The subject has severe forms of acne (e.g., acne conglobata, acne', 'fulminans) or secondary acne form (e.g. ,chloracne, drug-induced acne, etc.).']"
9,page_10,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 10 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'CCI', '8.', 'The subject has any uncontrolled or serious disease or any medical or', 'surgical condition that may either interfere with the interpretation of the trial', 'results and/or put the subject at significant risk (according to the', ""Investigator's judgment) if the subject takes part to the trial."", '9.', 'The subject has known or suspected allergies or sensitivities to any', ""components of any of the study drugs (see Investigator's Brochure)."", 'Investigational product:', 'Location of treated area:', 'Face: Chin, left cheek, right cheek, nose, and forehead', 'Truncal region : right and left upper back, right and left shoulders and right and left', 'upper anterior chest', 'Efficacy Assessments :', 'Efficacy endpoints', '.', 'Success Rate, defined as the percentage of subjects who achieve an IGA score', 'of 1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from', 'Baseline to Week 12 and Week 24', 'CCI', '.', 'Success Rate, defined as the percentage of subjects who achieve a PGA score of', '1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline', 'to Week 12 and Week 24', 'CCI', '. Percent change in facial non-inflammatory lesion counts from Baseline to week', '12 and week 24.']"
10,page_11,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 11 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Percent change in facial inflammatory lesion counts from Baseline to week 12 and', 'week 24.', 'Percent change in truncal non-inflammatory lesion counts from Baseline to week', '12 and week 24.', 'Percent change in truncal inflammatory lesion counts from Baseline to week 12', 'and Week 24.', ""Subject's assessment of facial acne improvement"", 'Safety assessment:', 'Safety assessments will be conducted for all subjects at Screening/baseline and all', 'subsequent visits until the Week 24 Visit. The safety parameters are Adverse Events,', 'local tolerability assessments.', 'Measurement criteria', 'Subject-reported outcomes', 'Quality Of Life questionnaires:', 'Dermatology Life Index questionniare (DLQI) questionnaires comparing', 'Baseline to Weeks 12 and 24 or Early termination', 'CompAQ (for >16 years age) comparing Baseline to Weeks 12 and 24', 'or', 'Early termination', 'EQ-5D-5L comparing Baseline to Weeks 12 and 24 or Early termination', 'Subject satisfaction questionnaire at Week 12/24/Early termination', 'Efficacy', ""Investigator's Global Assessment (IGA): acne severity of the face on a scale"", 'from 0 (Clear) to 4 (Severe) at each visit. Total lesion, non-inflammatory', 'lesion (open and closed comedones), inflammatory lesion (papules,', 'pustules) on the face (including the nose) at each visit', 'Physician Global Assessment (PGA): acne severity of the trunk on a scale', 'from 0 (Clear) to 4 (Severe) at each visit. Total lesion, non-inflammatory', 'lesion (open and closed comedones), inflammatory lesion (papules,', 'pustules) on trunk at each visit', 'Safety', 'Local tolerability parameters (erythema, scaling, dryness', 'and', 'stinging/burning) will be evaluated at each visit on a 4-point scale ranging', 'from 0 (none) to 3 (severe).', 'CCI', 'Adverse Events which includes AEs, SAE, AESI and Death', 'Other', 'CCI']"
11,page_12,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 12 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Analysed variables', 'Subject-reported outcomes', 'DLQI/cDLQI and CompAQ at Baseline and Week 12, 24/Early termination', 'Subject satisfaction questionnaires at Week 12, 24/Early termination', 'EQ-5D-5L at baseline and Week 12, 24/Early termination', 'Efficacy variable', 'Percent change in the facial IL NI', 'CC', 'lesion count from', 'Baseline to Weeks 12 and 24', 'CCI', 'Percent change in the trunk IL, NI', 'CC', 'lesion count from', 'Baseline to Weeks 12 and 24', 'Success rate of IGA as the percentage of subjects who achieved an IGA', 'with a score of 1 (almost clear) or 0 (Clear) AND an at least a 2-grade', 'improvement from Baseline at each study visit.', 'Success rate of PGA as the percentage of subjects who achieved a PGA', 'with a score of 1 (almost clear) or 0 (Clear) AND an at least a 2-grade', 'improvement from Baseline at each study visit.', 'CCI', 'Safety variables', 'Local tolerability parameters will be assessed at Baseline and each post', 'baseline visits, on all treated areas.', 'Local tolerance: Raw value at each visit and worst-score across vist, % of', 'Subjects across scores at each post-baseline visit', 'Incidence of adverse events (AESI, SAEs, Death, leading to discontinuation', 'or early termination)', 'Other', 'Principal statistical method:', 'The Intent-to-Treat (ITT) population consists of all enrolled subjects. The Safety', 'population (SAF) consists of the ITT population, who applied at least one dose of', 'treatment.', 'The main objective of this study is to evaluate the subject reported outcomes with', 'trifarotene with 12 and up to 24 weeks of treatment.', 'All variables will be descriptively summarized. All safety endpoints will be sumarized', 'based on SAF population and Quality of life and Efficacy endpoints will be sumarized']"
12,page_13,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 13 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'using ITT population. The last observation carried forward (LOCF) method will be used', 'to impute missing efficacy values where applicable.', 'There is no formal hypothesis to be tested. An estimation approach will be performed.', 'Point estimate and 95% confidence interval will be constructed where possible.', 'Approximately 50 subjects will be enrolled to evaluate the subject reported outcomes', '(quality of life and satisfaction survey). The sample size is not based on any formal', 'hypothesis testing.', 'Table 1', 'Clinical trial schematic', 'CC']"
13,page_14,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 14 of 88', 'Table 2', 'Schedule of assessments', 'CCI']"
14,page_15,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 15 of 88']"
15,page_16,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 16 of 88', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation Term', '°C', 'Degrees Celsius', '°F', 'Degrees Fahrenheit', 'AE', 'Adverse Event', 'AESI', 'Adverse Event of Special Interest', 'CDLQI', ""Children's Dermatology Life Quality Index"", 'CDMS', 'Clinical Data Management System', 'CRA', 'Clinical Research Associate', 'CRF', 'Case Report Form', 'CRO', 'Contract Research Organization', 'CSO', 'Clinical Safety Officer', 'CSR', 'Clinical Study Report', 'DLQI', 'Dermatology Life Quality Index', 'DMP', 'Data Management Plan', 'EDC', 'Electronic Data Capture', 'e.g.', 'For Example (Latin: exempli gratia)', 'ET', 'Early Termination', 'etc.', 'Et cetera', 'FDA', 'Food and Drug Administration', 'FSI', 'First Subject In (first subject screened, i.e. who signs the Informed Consent Form)', 'GCP', 'Good Clinical Practice', 'HIPAA', 'Health Insurance Portability and Accountability Act of 1996', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed Consent Form', 'ICH', 'International Conference on Harmonization', 'i.e.', 'That is (Latin: id est)', 'IEC', 'Independent Ethics Committee', 'IGA', ""Investigator's Global Assessment"", 'IND', 'Investigational New Drug', 'IRB', 'Institutional Review Board', 'ITT', 'Intention-to-treat', 'ITTT', 'Intent-to-treat on the Trunk', 'IUD', 'Intrauterine Device', 'LOAEL', 'Lowest-observed-adverse-effectlevel']"
16,page_17,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 17 of 88', 'Abbreviation Term', 'LOCF', 'Last Observation Carried Forward', 'LSI', 'Last Subject In (Last subject enrolled/randomized)', 'LSO', 'Last Subject Out (Last subject who completed his/her last clinical trial visit)', 'MI', 'Multiple Imputation', 'MD', 'Medical Doctor', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mL', 'Milliliter', 'NOAEL', 'no observed adverse effect level', 'OTC', 'Over-the-Counter', 'PGA', 'Physician Global Assessment', 'PK', 'Pharmacokinetics', 'PP', 'Per-Protocol', 'PT', 'Preferred term', 'RAR', 'Retinoic Acid Receptor', 'RXR', 'Retinoic X Receptor', 'SAE', 'Serious Adverse Event', 'SAP', 'Statistical Analysis Plan', 'SAF', 'Safety', 'SAFT', 'Safety Population on the Trunk', 'SIN', 'Subject Identification Number', 'SOC', 'System Organ Class', 'SOP', 'Standard Operating Procedure', 'SPF', 'Sun Protection Factor', 'TEAE', 'Treatment-Emergent Adverse Event', 'UPT', 'Urine Pregnancy Test', 'USA', 'United States of America', 'UV', 'Ultraviolet']"
17,page_18,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 18 of 88', '1', 'BACKGROUND AND RATIONALE', '1.1', 'Medical background and short rationale for the clinical trial', 'Acne is one of the most common skin disorders treated by dermatologists. While acne is highly', 'prevalent in youth with around 85% of teenagers affected at some point in time.¹ In European', 'populations over 70-80 % of all males will experience acne in some point of their lifetime. In the', 'USA, acne has been reported to affect an estimated number of over 25 (17-45) million Americans.²', 'As acne is a chronic and relapsing disease, normalizing follicular desquamation is then the key to', 'achieve and maintain control of acne. It can persist for years and result in disfigurement and', 'permanent scarring, and may have serious adverse effects on psychosocial development, resulting', 'in emotional problems, withdrawal from society, and depression.3 Teenagers with even mild acne', 'feel stigmatized and frustrated.4 Today it is established that retinoids acts in the pathology of acne', 'vulgaris: it is a potent modulator of cellular differentiation and keratinisation. Topical retinoids', 'have been the first-line treatment for most forms of acne vulgaris.5', 'Acne is a multifactorial inflammatory disease affecting pilosebaceous follicles. 6,7,2', 'Both clinically', 'and pathophysiologically, truncal acne and facial acne are similar in terms of specific lesions (eg,', 'closed comedones, open comedones, papules and pustules etc.). Further, the management of', 'truncal acne vulgaris warrants an approach similar to what is used for the treatment of facial acne8.', 'Truncal acne has been estimated to occur in over half the number of acne patients even if facial', 'acne is the most common and often the most visible form of acne. In one study of patients referred', 'to a dermatology clinic, it was found more than 60 percent of individuals had back acne 9. In', 'another cohort of 696 patients, half of patients with facial acne were found to have coexistent', 'truncal involvement. Approximately 50% of patients who presented with acne vulgaris', 'demonstrated involvement on the chest and/or back, with more than 3% presenting with truncal', 'acne lesions alone. Interestingly, approximately 1 out of 4 patients who presented with both facial', 'and truncal acne involvement did not voluntarily mention the presence of truncal acne as part of', 'their presenting complaint. In such cases, the presence of truncal acne lesions was detected by', 'clinical examination. The majority of patients presenting with truncal acne vulgaris exhibited mild', 'to moderate severity and more than 75% were interested in treatment for truncal acne lesions. 10', 'Trifarotene, a new generation topical retinoid with its unique mechanism of action, binds to', 'specific retinoic acid receptor (RAR-s). 11 Current evidence suggests that topical Trifarotene', 'normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone', 'formation. It may be an ideal topical agent with high selectivity towards gamma receptors, skin', 'metabolism and with very low systemic absorption for management of acne treatment. Currently', 'under clinical development with studies in acne vulgaris of face and trunk. However, it is also', 'important in terms of patient-reported outcomes (PRO) to assess satisfaction that might be caused', 'by the treatment or by acne itself and to also assess the local tolerability.', 'Proper skin care is considered to be an important component of the total management plan for', 'patients with acne vulgaris. There are several ways to mitigate adverse effect and prevent further', 'worsening of skin tolerability. These include initiating patients on lower concentrations of topical', 'retinoids, choosing cream or lotion (rather than gel). Trifarotene, being a highly selective RAR-x']"
18,page_19,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 19 of 88', 'with low concentration and in cream formulation with adequate recommendations for its use,', 'would be appropriate in acne subjects. Skin irritation can lead to poor compliance and subsequently', 'lack of efficacy. Therefore, adapted treatment instructions for use especially during the first weeks', 'of treatment may result in a better tolerability, leading to improved compliance, efficacy, and', 'patient satisfaction. Hence, the addition of a topical gentle moisturizer for these subjects and', 'recommendation for avoiding sun exposure is a part of the skin care regimen for these acne', 'subjects. 12, 13 Minimizing skin irritation and photoprotection can be achieved by the use of non-', 'comedogenic moisturizers with appropriate sun protection factor (SPF) of 30 or higher can hydrate', 'and protect the skin from UV irradiation.', '14, 15, 16', 'Acne can persist for years and may seriously affect the psychosocial development, resulting in', 'emotional problems, withdrawal from society, and depression.3 If not treated, acne may cause', 'serious physical and emotional scarring and can significantly impact the quality of life of those', 'affected', ""by the disease. 17 Therefore, this study aims to evaluate acne subject's satisfaction and"", 'quality of life with Trifarotene medication, as it is known for topical retinoids to be sensitive on', 'skin. The local tolerance of the treatment in terms of erythema, scaling, dryness, stinging/burning', 'will also be evaluated.', 'This clinical trial is designed to evaluate the PRO with use of Trifarotene in subjects with moderate', 'facial and truncal acne vulgaris and also to assess the impact of such treatment instructions on', 'overall efficacy, subject satisfaction, and safety, with management of skin irritation which was not', 'specifically evaluated during the clinical development.', '1.2', 'Drug profile', 'Retinoids play a central part in the treatment of acne due to their keratolytic activity and', 'modulation of proliferation and differentiation of keratinocytes leading to the elimination of the', 'comedone. 18', 'Retinoids exert their effects on a molecular level through nuclear receptors: Retinoic Acid', 'Receptor (RAR) and Retinoic X Receptor (RXR), which each have three sub-types ß and Y.', 'Trifarotene, developed by GALDERMA R&D for topical administration, shows selective binding', 'to RAR and not to RXR.', '1.3', 'Risk/benefit assessment', 'The most serious risk associated with retinoids is related to teratogenicity and embryotoxicity.', 'Systemic exposure to Trifarotene, like all retinoids, may cause fetal harm following systemic', 'exposure in pregnant women.']"
19,page_20,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 20 of 88', 'CCI', 'Taken the documented effectiveness of Trifarotene cream 50g/g in the treatment of acne,', 'the risk/benefit assessment is supportive of the study.', '2', 'CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS', '2.1', 'Clinical trial objectives', 'The purpose of this study is to evaluate subject reported outcomes with Trifarotene cream.', '2.2', 'Clinical hypotheses', 'CCI']"
20,page_21,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 21 of 88', '3', 'OVERALL CLINICAL TRIAL DESCRIPTION', 'Multi-center study for Trifarotene cream applied once daily for 24 weeks in the evening.', 'Trifarotene 50g/g cream applied once daily', '3.1', 'Efficacy assessment', 'The efficacy endpoint consists of the following endpoints:', 'Success Rate, defined as the percentage of subjects who achieve an IGA score of', '1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline to', 'Week 12 and Week 24', 'Success Rate, defined as the percentage of subjects who achieve a PGA score of', '1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline to', 'Week 12 and Week 24', 'Percent change in facial non-inflammatory lesion counts from Baseline to week 12 and', 'week 24.', 'Percent change in facial inflammatory lesion counts from Baseline to week 12 and week', '24.', 'Percent change in truncal non-inflammatory lesion counts from Baseline to week 12 and', 'week 24.', 'Percent change in truncal inflammatory lesion counts from Baseline to week 12 and', 'Week 24.', '3.2', 'Safety Assessment', 'Safety evaluations will be performed at Baseline and at Weeks 1, 4, 12, 18, and', '24/Early Termination (ET)/Unscheduled visits. These evaluations will consist of assessment of', 'local tolerability and adverse events at each visit.', 'CCI']"
21,page_22,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 22 of 88', 'CCI']"
22,page_23,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 23 of 88', '4', 'CLINICAL TRIAL DURATION AND TERMINATION', 'The planned clinical trial duration (from FSI to LSO) is approximately', 'The date of end', 'of the clinical trial is defined as the date of the last visit of the last subject who participates in the', 'trial.', 'The planned duration of recruitment (i.e. From FSI to LSI) is approximately CCI', 'Prior to subject enrolment, a screening period lasting', 'CC', 'at', 'the maximum is authorized.', 'Clinical trial participation for each subject is approximately CCI', 'GALDERMA may decide to prematurely terminate or suspend the participation of a particular', 'clinical trial center (e.g., for non-inclusion or non-compliance with protocol, regulations, or GCP)', 'or prematurely suspend the clinical trial (e.g., for safety, study drug quality, regulatory, efficacy,', 'or logistical reasons) at any time, with appropriate notification.', '5', 'SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION', '5.1', 'Number of subjects', 'CCI', '5.2', 'Clinical trial population characteristics', 'In order to be eligible for the trial, subjects must fulfill all of the following criteria at Baseline visit.', 'Some criteria are to be checked at the Screening visit. Subjects may be re-screened once unless the', 'reason for screen failure is related to acne severity (IGA or PGA) or lesion counts.', '5.3', 'Inclusion criteria', '1.', 'The subject is a male or female, 9 years of age and older, at Screening visit.', '2.', 'Subject with clinical diagnosis of acne vulgaris,']"
23,page_24,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 24 of 88', ""a) Investigator's Global Assessment (IGA) score of 3 (Moderate)"", 'CCI', 'b)', 'Truncal acne severity grade of 3 (moderate) on the Physician Global assessment (PGA)', 'scale CCI', '3.', 'In general good health (physical, mental, and social well-being, not merely the absence of', 'disease/infirmity), according to subject self-report.', '4.', 'Having Fitzpatrick skin phototype I-VI (refer to Fitzpatrick Skin Classification).', '5.', 'The subject is a female of non-childbearing potential (pre-menarcheal or postmenopausal', '[absence of menstrual bleeding for 1 year prior to Screening, without any other medical', 'reason], hysterectomy or bilateral oophorectomy).', '6.', 'The subject is a female of childbearing potential:', '6.1.', 'With a negative urine pregnancy test (UPT) at Screening and Baseline visits,', '6.2.', 'Who are willing to take UPTs throughout the course of the study.', '6.3.', 'Who has been strictly abstinent for 1 month prior to Screening/Baseline and agrees to', 'continue for the duration of the clinical trial and at least 1 month after the last study', 'drug application,', 'OR', 'Who agrees to use an effective and approved contraceptive method(s) for the duration', 'of the study and at least 1 month after the last study drug application. An effective', 'method of contraception is defined as:', '6.3.a.', 'bilateral tubal ligation;', '6.3.b.', 'approved combined oral contraceptives (estrogens and progesterone), implanted or', 'injectable contraceptives, or hormonal contraceptive vaginal rings with a stable', 'dose for at least 1 month prior to the Screening/Baseline visit;', '6.3.c.', 'hormonal intra uterine device (IUD) inserted at least 1 month prior to the', 'Screening/Baseline visit;', '6.3.d.', 'vasectomized partner for at least 3 months prior to the Screening/Baseline visit.', '7.', 'If a female of childbearing potential uses combined oral contraceptives approved as acne', 'treatments (e.g., Ortho Tri-Cyclen®, YazR, Diane-358, the dose should be stable for at', 'least 6 months prior to the Screening/Baseline visit.', '8.', 'For a pre-menstrual female who begins menses during the study:']"
24,page_25,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 25 of 88', '8.1.', 'Agrees to be strictly abstinent for the duration of the clinical trial and at least 1 month', 'after the last study drug application,', 'OR', '8.2.', 'Agrees to use an effective and approved contraceptive method(s) for the duration of', 'the study and at least 1 month after the last study drug application and agrees to', 'undergo pregnancy tests. An effective method of contraception is defined as approved', 'combined oral contraceptives (oestrogens and progesterone), implanted or injectable', 'contraceptives, or hormonal intra-uterine device (IUD) or hormonal contraceptive', 'vaginal rings.', 'CC', '10.', 'The subject agrees to participate in the study, verified by dating and signing an approved', 'written Informed Consent Form (ICF) or for subjects under age of majority, an assent form', 'signed by the subject (if required) in conjunction with an ICF signed by the parent(s)/legal', 'representative at the Screening visit before any study procedures.', 'CCI', '12. Apprised of HIPAA (Health Insurance Portability and Accountability Act) and is willing to', 'share personal information and data, as verified by signing a written authorization at the', 'Screening/Baseline visit.', 'CCI', 'For subjects under the age of 18:', '15. Having a parent or legal guardian who is 18 years of age or older and presents proof of', 'guardianship (eg, insurance card, certificate of residence, or copy of officially issued', 'family registration) at screening/baseline visit.', '5.4', 'Exclusion criteria', '1.', 'Subject with severe acne (IGA or PGA > 3).', '2.', 'The subjects has severe forms of acne (eg, acne conglobate, acne fulminans) or secondary', 'form (eg. Chloracne, drug-induced acne, etc).']"
25,page_26,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 26 of 88', '3.', 'The subject has any acne cyst on the face at Screening and Baseline.', '4.', 'The subject has any acne cysts on the trunk at Screening and Baseline.', 'CCI']"
26,page_27,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 27 of 88', 'CCI']"
27,page_28,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 28 of 88', '5.5', 'Previous and concomitant therapies', '5.5.1', 'Definition', 'CCI', 'Concomitant therapies are defined as follows:', 'any existing therapies ongoing at the baseline visit or starting after the baseline visit, or', 'any changes to existing therapies (such as changes in dose or formulation) during the course of', 'the clinical trial, or', 'any new therapies received by the subject with start on or after the baseline visit', 'Any new concomitant therapy or modification of an existing therapy may be linked to an', 'adverse event (AE). A corresponding Adverse Event Form must be completed to account for', 'the change in therapy, except in some cases such as therapy used for prophylaxis, dose', 'modification (done during visit or by call) for a chronic condition, etc.', '5.5.2', 'Categories', 'The following two categories are to be considered for previous and concomitant therapies:', 'Drugs/therapies including, but not limited to, prescription, over-the-counter (OTC), birth', 'control pills/patches/hormonal devices, vitamins, moisturizers, sunscreens, herbal', 'medicines/supplements, and homeopathic preparations.', 'Medical and surgical procedures including, but not limited to, laser/radiation procedures,', 'dermal fillers, X-rays (excluding dental X-rays), etc.', '5.5.3', 'Recording']"
28,page_29,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 29 of 88', 'Previous and concomitant therapies are to be recorded on the Drugs/Therapies form', '(for drugs/therapies) and/or on the Medical and Surgical Procedures form (for medical/surgical', 'procedures) in the case report form (CRF).', 'Concomitant therapies (including preferred or provided moisturizer) are to be recorded, reviewed,', 'and updated at each visit. Every attempt should be made to keep concomitant therapy dosing and', 'regimen constant during the trial.', '5.5.4', 'Authorized concomitant therapies', 'Unless listed under the exclusion criteria (Section 5.4 item [15]) or in prohibited concomitant', 'therapies, the following therapies are allowed, as long as they are not indicated for the treatment', 'of acne vulgaris (see Section 5.5.5):', 'Topical treatments:', 'In addition to the study drug, the following', 'CCI', 'products are authorized on the treated areas if', 'they are not indicated for the treatment of Acne Vulgaris:', 'CCI', '5.5.5', 'Prohibited concomitant therapies', 'CCI']"
29,page_30,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 30 of 88', 'CCI', 'If prohibited therapies become a necessary treatment for the safety or best interest of the subject,', 'GALDERMA should be notified to discuss possible alternatives prior to administration of a', 'prohibited therapy.', 'If a subject receives prohibited therapy during the clinical trial, GALDERMA should be notified', 'to discuss the pertinence and the modalities for the subject to continue in the clinical trial.', '5.6', 'Procedures/reasons for subject discontinuation', 'An Investigator may decide to discontinue a subject from the clinical trial for safety reasons.', 'Although the importance of completing the entire clinical trial should be explained to the subject', 'by the clinical trial personnel, any subject is free to discontinue his/her participation in this clinical', 'trial at any time and for whatever reason, specified or unspecified, and without any prejudice. No', 'constraints are to be imposed on the subject, and when appropriate, a subject may be treated with', 'other conventional therapy when clinically indicated.', 'When a subject does not complete the clinical trial, he/she will be fully assessed, if such assessment', 'is possible. The procedures designated for the Week 24/Early Termination visit should be', 'completed for all subjects discontinuing the clinical trial and the appropriate CRF page should be', 'completed.', 'All discontinuations and the reason for discontinuation are to be documented by the Investigator', 'on the Exit Form, and also on the Adverse Event Form for discontinuation due to an AE.', 'For discontinuation due to an AE, the Investigator should ensure that the subject receives suitable', 'therapy for his/her AE.', 'A subject who has been enrolled and assigned a kit number cannot be replaced by another subject', 'if he/she discontinues the clinical trial for any reason.', ""GALDERMA R&D may also decide to prematurely terminate or suspend a subject's participation"", 'in the clinical trial.', 'Potential reasons for discontinuation, as listed on the Exit Form, are defined in Table 3 below:']"
30,page_31,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 31 of 88', 'Table 3', 'Exit Form reasons for discontinuation', 'Pregnancy:', 'Withdraw the Subject from the clinical trial and follow the procedure described in', 'Section 7.2.2.2.5.', 'Lack of Efficacy:', 'Investigator judgment only: based on therapeutic/disease-state expectations. If subject', 'opinion only, mark ""subject request"" and document it in the comment section of the Exit', 'Form.', 'Adverse Event:', 'Complete an Adverse Event Form.', 'Subject Requesta:', 'Includes consent withdrawal, subject relocation, schedule conflicts. Explain the reason for', 'withdrawal in the comment section of the Exit Form. If a subject withdraws consent', 'because of an adverse event, the reason for discontinuation should be Adverse Event', 'Protocol Violation:', 'Explain the violation in the comment section of the Exit Form.', 'Lost to Follow-up:', 'Confirmed with two documented phone calls and a certified letter (delivery receipt', 'requested) without answer. Explain in the comment section of the Exit Form.', 'Othera:', 'This category is to be used for a subject who discontinues due to a reason other than as', 'specified in the predefined categories above. Explain the reason for discontinuation in the', 'comment section of the Exit Form.', 'a) If reason for discontinuation is ""subject request"" or ""other"", the subject will be questioned to rule out the possibility of an AE (this', 'should be documented in the comment section of the Exit Form).']"
31,page_32,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 32 of 88', '6', 'CLINICAL SUPPLIES', '6.1', 'Clinical supply identification and use', '6.1.1', 'Study drug description', 'Table 4', 'Description and usage of the study drug', 'Investigational Product', 'Trade Name or Equivalent', 'N/A', 'Name of Drug Substance', 'Trifarotene', 'Internal Code', 'CCI', 'Pharmaceutical Form', 'Cream', 'Strength/ Concentration', '50 g/g', 'CCI', 'Location of Treated', 'Face and truncal region', 'CCI', 'Area', 'CCI', 'N/A=not applicable']"
32,page_33,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 33 of 88', '6.1.2', 'Subject identification number', 'Upon signature of the ICF (and Assent for minor subjects) each subject will be assigned a Subject', 'Identification Number (SIN) by the designated study personnel.', 'CCI', '6.1.3', 'Kit number', 'The kit number, a unique number corresponding to the number on the label of the study drug, will', 'be assigned to each eligible subject at Baseline.', 'CCI', 'CCI', '6.1.4', 'Instructions for use and application', 'Each subject will receive both oral and written instructions for the proper dosing and study', 'treatment application techniques.', 'CCI', 'As well, the dosing calendar completion will be explained to each', 'subject at each dispensation visit.', 'Applications will be done by the subjects themselves at home in the evening.', 'CCI', 'Application on the face:', 'CCI']"
33,page_34,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 34 of 88', 'CCI', 'The study drug will be applied to the facial region which includes the forehead, nose, chin and', 'each cheek once daily in the evening after washing and drying.', 'The objective is to cover the face with a thin layer of the study drug,', 'One pump actuation should be enough', 'to cover the forehead, right cheek, left cheek, nose, and chin. Avoid application in/close to eyes,', 'or angles of the mouth, lips and mucous membrane.', 'CCI', 'Application on the trunk:', 'CCI', 'The study drug will be applied to the upper truncal regions', 'CCI', 'once daily in the evening after washing and drying.', 'The objective is to cover the reachable upper truncal region with a thin layer of the study drug,', 'CC', 'Two actuations of', 'the pump should be enough to cover right and left upper back area', 'CCI', 'and upper anterior right and left chest. Avoid application on the', 'axillary region and anterior and posterior neck.', 'The study drug should not be applied to cuts, abrasions, eczematous, or sunburned skin.', 'The daily dairy is to be completed by the subject (if needed, with the help of the legal guardian)', 'and returned to the site at each study visit.', '6.1.5', 'Other supplies']"
34,page_35,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 35 of 88', '6.2', 'Study drug packaging and labeling', 'Each subject kit is comprised of an outer box enclosing', 'CC', 'dispensing boxes labeled with an', 'affixed and a tear-off portion.', 'Each dispensing box will contain', 'CC', 'pumps, also with labeling.', 'The labels will be printed in the local language. The text of the label will detail the information', 'requested by Good Manufacturing Practice and local regulations.', '6.3', 'Supplies management', '6.3.1', 'Accountability', 'Upon receipt of the study drug, the site personnel responsible for managing the supplies must', 'conduct a complete inventory of all study drugs.', 'The investigator or designee will maintain accurate records of supplies received, inventoried at the', 'clinical trial site and used per subject.', 'CCI', 'All study drug sent to the Investigator/Institution will be accounted for and no unauthorized use is', 'permitted.', 'CCI', '6.3.2', 'Storage of clinical study drug']"
35,page_36,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 36 of 88', 'Study drug must be stored in a safe and secure area with restricted access; under the storage', 'conditions specified by GALDERMA R&D (see Table 4).', '6.3.3', 'Dispensing and return', '6.3.3.1', 'Dispensing', 'Designated study personnel at each investigational site will be responsible for dispensing the study', 'drug at the appropriate visits and will record the dispensing information for each subject.', '6.3.3.2', 'Return', 'Each subject will be instructed on the importance of returning their study drug bottle pumps (used', 'and/or unused)', 'Drug accountability will be', 'done upon return by the designated clinical trial center personnel.', 'CCI', 'For subjects who do not complete the entire clinical trial, all used and unused study drug should', 'be returned by the subjects to the defined personnel at the clinical trial center.', '6.3.4', 'Treatment compliance management and record', 'Subjects will be instructed by study personnel on the importance of being compliant with the use', 'of the study drug throughout the clinical trial.', 'A subject daily diary will be provided to the subject with clear direction from the study site', 'personnel at each dispensation visit. Each subject will complete the daily diary', 'CCI', 'Subjects', 'will also be questioned about the number of missed applications (if any) between study visits.']"
36,page_37,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 37 of 88', 'Treatment compliance will be assessed using the subject daily diary.', 'CCI', 'CCI', '6.4', 'Dose modification', 'Subjects are encouraged to use from the Baseline visit and throughout the study the provided', 'moisturizer,', 'CCI', 'Signs and symptoms of local cutaneous irritation assessed with a local tolerability scale will be', 'considered as Adverse Events', 'CCI', '7', 'CLINICAL TRIAL ASSESSMENT', '7.1', 'Efficacy assessments', 'IGA and PGA assessments are to be performed by a qualified evaluator.', 'CCI', 'CCI', '7.1.1', 'Efficacy measurements', 'IGA/PGA and Lesion Counts will be performed for face and trunk separately. CCI', 'Refer to Appendix 13.8.']"
37,page_38,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 38 of 88', 'CCI', '7.1.1.1', ""IGA (Investigator's global assessment) of facial acne"", 'The areas defined for IGA assessment are forehead, each cheek, chin, and nose. IGA will be', 'confined to a global assessment of each area defined above.', 'CCI', 'The IGA will be assessed', 'according to the following scale:', ""Investigator's Global Assessment Scale (IGA) Face"", '0', 'Clear', 'Clear skin with no inflammatory or non-inflammatory lesions.', '1', 'Almost Clear', 'A few scattered comedones and a few small papules.', '2', 'Mild', 'Easily recognizable; less than half the surface is involved. Some comedones and some', 'papules and pustules.', '3', 'Moderate', 'More than half of the surface is involved. Many comedones, papules and pustules. One', 'nodule may be present.', '4', 'Severe', 'Entire surface is involved. Covered with comedones, numerous papules and pustules.', 'Few nodules may be present.', '7.1.1.2', 'PGA (Physician Global Assessment) of truncal acne', 'The areas defined for PGA assessment are shoulders, upper back, and upper anterior chest which', 'are accessible to self-application by the subject, i.e., the regions that the subject can easily reach', 'and apply the study drug without assistance.', 'PGA will be confined to a global assessment of each areas defined above. The PGA is a snapshot', 'static assessment to be done prior to detailed lesion counts.', 'CCI']"
38,page_39,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 39 of 88', 'The PGA is outlined in the following table', 'CC', 'Physician Global Assessment Scale (PGA) Trunk', '0', 'Clear', 'Clear skin with no inflammatory or non-inflammatory lesions.', '1', 'Almost Clear', 'A few scattered comedones and a few small papules.', '2', 'Mild', 'Easily recognizable; less than half the surface is involved. Some comedones and some', 'papules and pustules.', '3', 'Moderate', 'More than half of the surface is involved. Many comedones, papules and pustules. One', 'nodule may be present.', '4', 'Severe', 'Entire surface is involved. Covered with comedones, numerous papules and pustules.', 'Few nodules may be present.']"
39,page_40,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 40 of 88', 'CCI', '7.1.2', 'Efficacy endpoints', '.', 'Efficacy Endpoint: The efficacy endpoint consists of the following:', 'Success Rate, defined as the percentage of subjects who achieve an IGA score of 1 (Almost', 'Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline to Week 12 and Week', '24']"
40,page_41,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 41 of 88', 'CCI', 'Success Rate, defined as the percentage of subjects who achieve a PGA score of 1 (Almost', 'Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline to Week 12 and Week', '24', 'Percent change in facial non-inflammatory lesion counts from Baseline to week 12 and week', '24.', 'Percent change in facial inflammatory lesion counts from Baseline to week 12 and week 24.', 'Percent change in truncal non-inflammatory lesion counts from Baseline to week 12 and', 'week 24.', 'Percent change in truncal inflammatory lesion counts from Baseline to week 12 and Week', '24.', '7.2', 'Safety assessment', 'The safety parameters are the recording of adverse events and local tolerability scores as specified', 'in section 7.2.1.', '7.2.1', 'Local tolerability assessment (of face and of trunk)', 'Erythema, scaling, dryness will be evaluated by the investigator separately on the face and trunk,', 'CCI', 'These tolerability signs and symptoms will be assessed for the face and the trunk separately and', 'will be graded at baseline and at each follow up visit based on the below scale:', 'Erythema - abnormal redness of the skin', 'None', '0', 'No erythema', 'Mild', '1', 'Slight pinkness present', 'Moderate', '2', 'Definite redness, easily recognized', 'Severe', '3', 'Intense redness', 'Scaling - abnormal shedding of the stratum corneum', 'None', '0', 'No scaling']"
41,page_42,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 42 of 88', 'Mild', '1', 'Barely perceptible shedding, noticeable only on light scratching or rubbing', 'Moderate', '2', 'Obvious but not profuse shedding', 'Severe', '3', 'Heavy scale production', 'Dryness - brittle and/or tight sensation', 'None', '0', 'No dryness', 'Mild', '1', 'Slight but definite roughness', 'Moderate', '2', 'Moderate roughness', 'Severe', '3', 'Marked roughness', 'Stinging/Burning - pricking pain sensation immediately after dosing', 'None', '0', 'No stinging/burning', 'Mild', '1', 'Slight warm, tingling/stinging sensation; not really bothersome', 'Moderate', '2', 'Definite warm, tingling/stinging sensation that is somewhat bothersome', 'Severe', '3', 'Hot, tingling/stinging sensation that has caused definite discomfort', '7.2.2', 'Adverse events', 'Adverse events are to be monitored throughout the course of the clinical trial. All AEs are to be', 'reported on the Adverse Event Form with complete information as required. If AEs occur, the main', 'concern will be the safety of the subjects. At the time of the ICF signature, each subject must be', 'provided with the name and phone number of clinical trial center personnel for reporting AEs and', 'medical emergencies.', '7.2.2.1', 'Definitions', '7.2.2.1.1', 'Adverse events']"
42,page_43,"['GALDERMA R&D', 'RD.06.SPR.118291 Protocol V02 04Jun2019', 'Page 43 of 88', 'According to ICH E2A, an AE is any untoward medical occurrence in a subject or clinical', 'investigation subject administered a pharmaceutical product and which does not necessarily have', 'a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended', 'sign (including an abnormal laboratory value), symptom, or disease temporally associated with the', 'use of a medicinal (investigational) product, whether or not related to the medicinal', '(investigational) product.', 'Thus any new sign, symptom or disease, or any clinically significant worsening of an existing sign,', 'symptom or disease compared to the condition at the first visit (including disease treated), should', 'be considered as an AE. Lack of efficacy is not considered as an AE.', 'Each new episode of a chronic disease (e.g., hay fever, allergy, etc.) should be reported as', 'a new AE.', 'Notes:', 'Any new sign or symptom reported by the subject that appears after accidental or intentional', 'overdose or misuse should also be reported as an AE.', 'There should be an attempt to report a diagnosis rather than the signs, symptoms or abnormal', 'laboratory values associated with the report of an AE. However, a diagnosis should be reported', ""only if, in the Investigator's judgment, it is relatively certain. Otherwise, symptoms, signs, or"", 'laboratory values should be used to describe the AE.', 'Pregnancy is not to be considered as an AE; however, is an important medical event that must', 'be monitored as described in Section 7.2.2.2.5.', '7.2.2.1.2', 'Serious Adverse events', 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:', 'Results in death,', 'Is life-threatening,', 'Requires inpatient hospitalization or prolongation of existing hospitalization,', 'Results in persistent or significant disability/incapacity, or', 'Is a congenital anomaly/birth defect.', 'Important medical events that may not result in death, be life-threatening, or require hospitalization', 'may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize', 'the safety of the subject and may require medical or surgical intervention to prevent one of the', 'outcomes listed in this definition. Examples of such events are intensive treatment in an emergency', 'room or at home for allergic bronchospasm, blood dyscrasia, or convulsions that do not result in', 'hospitalization.']"
43,page_44,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 44 of 88', 'Note:', 'The term ""life-threatening"" refers to an event in which the subject was at risk of death at the time', 'of the event; it does not refer to an event that hypothetically might have caused death if it was more', 'severe.', 'Inpatient hospitalization is considered to have occurred if the subject has had to stay for a night at', 'the hospital. The criterion for prolongation of hospitalization is also defined as an extra night at', 'the hospital. Hospitalization may not constitute sufficient grounds to be considered as an SAE if it', 'is solely for the purpose of a diagnostic tests (even if related to an AE), elective hospitalization for', 'an intervention that was already planned before subject enrollment in the clinical trial, admission', 'to a day-care facility, social admission (e.g., if the subject has no place to sleep), or administrative', 'admission (e.g., for a yearly examination).', '7.2.2.1.3', 'Adverse Events of Special Interest', 'An AESI is a noteworthy event for the particular study drug that can be appropriate to monitor', 'closely. It could be serious or non-serious and AESIs could include events that might be potential', 'precursors or prodromal symptoms for more serious medical conditions in susceptible individuals.', 'CCI', 'For AESIs, the Investigator is required to complete the Adverse Event Form and follow the AESI', 'reporting procedures in Section 7.2.2.2.3 even if the event is considered non-serious according to', 'the usual regulatory criteria. For suspected sensitizations follow challenge and re-challenge patch', 'test procedures in Section 7.2.2.2.4.', '7.2.2.1.4', 'Unexpected adverse drug reaction', 'According to ICH E6, an unexpected adverse drug reaction is defined as an adverse reaction, the', 'nature or severity of which is not consistent with the applicable study drug information (e.g., IB', 'for an unapproved investigational product or the package insert/summary of product characteristics', 'for an approved product).', '7.2.2.1.5', 'Adverse event reporting period', 'The clinical trial period during which AEs must be reported is the period from when the subject', ""signed the ICF to the end of the subject's participation.""]"
44,page_45,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 45 of 88', 'The Sponsor should be informed if the Investigator becomes aware of any unusual safety', 'information or any safety information that appears to be drug-related involving a subject who has', 'participated in a clinical trial, even after a subject has completed the clinical trial. The Investigator', 'should be diligent in looking for possible latent safety effects that may not appear until', 'a', 'medication has been discontinued.', '7.2.2.1.6', 'Severity', 'Severity is a clinical determination of the intensity of an AE and not of a disease.', 'The Investigator is to classify the intensity of AEs using the following definitions as a guideline', 'for all AEs occurring during clinical trials conducted or sponsored by GALDERMA. For this', 'classification, the Investigator will take into account the possible range of the intensity of the event', 'and report the grade of intensity which is the most appropriate according his medical judgment.', 'Mild', 'Awareness of signs or symptom, but easily tolerated.', 'Moderate', 'Discomfort, enough to cause interference with usual activity', 'Severe', 'Incapacitating with inability to work or perform usual activity', '7.2.2.1.7', 'Relationship to the study drug', 'The Investigator is to determine whether there is a reasonable causal relationship between the study', 'drug and the AE. Medical judgment should be used to determine the relationship, considering all', 'relevant factors including the pattern of reaction, temporal relationships, positive challenge or', 'rechallenge, relevant medical history, and confounding factors such as co-medication or', 'concurrent diseases.', 'The expression ""reasonable causal relationship"" is meant to convey in general that there are facts', 'or arguments to suggest a causal relationship (ICH E2A, Section IIIA 1).', 'The relationship assessment for an AE is to be completed using the following definitions as a', 'guideline for all AEs occurring during clinical trials conducted or sponsored by', 'GALDERMA R&D:', 'Reasonable possibility:', 'According to the reporting Investigator, there is a reasonable possibility (i.e., suggestive', 'evidence or arguments) that there is a causal relationship irrespective of the dose administered', 'between:', 'The study drug (investigational product and the AE),', 'The clinical trial protocol procedure (such as blood test) and the AE.']"
45,page_46,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 46 of 88', 'No reasonable possibility:', 'No suggestive evidence or arguments can be identified regarding a causal relationship between the', 'study drug or the clinical trial protocol procedure and the AE.', '7.2.2.2', 'Reporting procedures', '7.2.2.2.1', 'Procedures for reporting adverse events', 'The collection of AEs is from the time that a subject signs the ICF to their final visit.', 'At each post-enrollment visit, the Investigator (or sub-Investigator) will question the subject about', 'AEs using an open non-persuasive question to elicit reporting of AEs, for example: ""Have you', 'noticed any change in your health since the last visit?"" Directed questioning and examination will', 'then be performed, as appropriate.', 'Any AE occurring during the AE reporting period, whether it is related to the study drug or not,', 'will be recorded immediately in the source document, and described on the Adverse Event Form', 'along with the date of onset, severity, relationship to the study drug, and outcome, without omitting', 'any requested and known information. Additional information may be requested under certain', 'circumstances. Adverse Events assessed as related to the treatment will be monitored until they', 'are completely or satisfactorily resolved. Other AEs will be monitored until the last visit if they', 'are not resolved or satisfactorily resolved.', ""The Investigator will obtain and maintain in the subject's files all pertinent medical records,"", 'information and medical judgment from colleagues who assisted in the treatment and follow-up of', ""the subject. If necessary, the Investigator will contact the subject's personal physician or hospital"", 'staff to obtain further details.', 'For SAEs (see Section 7.2.2.2.2), AESIs (see Section 7.2.2.2.3), and pregnancies', '(see Section 7.2.2.2.5), the CSO is to be informed immediately by fax or email. The event must be', 'reported by facsimile or scan and sent by e-mail to the CSO within 24 hours of knowledge of the', 'event (contact details in Section 7.2.2.2.2).', '7.2.2.2.2', 'Procedure for reporting a Serious Adverse Event', 'For an SAE occurring during the period of the clinical trial, regardless of whether it is related to', 'the treatment or not, and of whether it is expected or not, the Investigator must do the following:', '1.', 'Take prompt and appropriate medical action, if necessary. The safety of the subject is the', 'first priority.', '2.', 'Immediately inform the CSO of the event by fax or email and discuss further actions to be', 'taken.']"
46,page_47,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 47 of 88', 'Investigator contact:', 'PPD', '3.', 'Complete the Adverse Event Form provided in the CRF as fully as possible.', '4.', 'Ensure that the event is classified as an SAE in the CRF.', '5.', 'Print and complete the Serious Adverse Event Form available in the electronic data capture', '(EDC) system as PDF document. Fax or scan and send by e mail the completed form,', 'accompanied by any other relevant information or medical records (e.g., laboratory test', 'results) within 24 hours to the CSO. The demographics, medical history, previous and', 'concomitant therapies, and adverse event pages of the CRF must be completed and', 'available for review in the EDC system at the time of the report.', '6.', 'Monitor and record the progress of the event until it resolves or reaches a clinically stable', 'outcome, with or without sequelae. For all additional follow-up evaluations, first inform', 'the CSO of the outcome by telephone, then fax or scan and send by e-mail all additional', 'follow-up information to the CSO within 24 hours. Serious Adverse Events will be', 'monitored until the Investigator and Sponsor agree that the event is satisfactorily resolved.', '7.', 'Obtain and maintain in his/her files all pertinent medical records, information, and medical', 'judgments from colleagues who assisted in the treatment and follow-up of the subject.', ""If necessary, contact the subject's personal physician or hospital staff to obtain further"", 'details.', '8.', 'Inform the CSO of the final outcome of the event. Send a revised or updated Serious', 'Adverse Event Form and Adverse Event Form, if appropriate.', '9.', 'Comply with the applicable regulatory requirement(s) related to the reporting of SAEs to', 'the Institutional Review Board (IRB) / Independent Ethics Committee (IEC).', '7.2.2.2.3', 'Procedure for reporting an adverse event of special interest', 'For any AESI (see Section 7.2.2.1.3) occurring during the period of the clinical trial, whether', 'related to the treatment or not, and whether expected or not, the Investigator is to do the following:', '1. Take prompt and appropriate medical action, if necessary. The safety of subjects is the first', 'priority.', '2. Immediately inform the CSO of the event by fax or email and discuss further actions to be', 'taken.', '3. Investigator contact: Refer to Section 7.2.2.2.2.', '4. Complete the Adverse Event Form provided in the CRF as fully as possible.', '5. Ensure that the event is classified as an AESI in the CRF.', '6.', 'Print the Adverse Event form. Fax or scan and send by e mail the completed form,', 'accompanied by any other relevant information or medical records (e.g. laboratory test']"
47,page_48,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 48 of 88', 'results) within 24 hours to the CSO. The demographics, medical history, previous and', 'concomitant therapies, and adverse event pages of the CRF must be completed and available', 'for review in the EDC system at the time of the report.', '7.', 'Monitor and record the progress of the event until it resolves or reaches a clinically stable', 'outcome, with or without sequelae. For all the additional follow-up evaluations, first inform', 'the CSO of the outcome by telephone, then fax or scan and send the additional follow-up', 'information by e-mail to the CSO within 24 hours. AESIs will be monitored until the', 'Investigator and Sponsor agree that the event is satisfactorily resolved.', '8.', 'Obtain and maintain in his/her files all pertinent medical records, information, and medical', 'judgments from colleagues who assisted in the treatment and follow-up of the subject.', ""If necessary, contact the subject's personal physician or hospital staff to obtain further"", 'details.', '9. Inform the CSO of the final outcome of the event. Send a revised or updated Adverse Event', 'Form, if appropriate.', '7.2.2.2.4', 'Procedures for suspected sensitization (Re-Challenge and patch Ingredient', 'Test)', 'If a subject experiences suspected skin sensitization (contact allergy), the following actions should', 'be taken to characterize the event:']"
48,page_49,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 49 of 88', 'CC', 'Table 5', 'Suspected sensitization - reaction grading', 'Score', 'Morphology', 'Interpretation', '-', 'No skin changes in the tested area', 'Negative', '?', 'Faint, non-palpable erythema', 'Doubtful reaction', '+', 'Palpable erythema (moderate edema or infiltrate), papules not', 'Weak positive reaction', 'present or scarce, vesicles not present', '++', 'Strong infiltrate, numerous papules, vesicles present', 'Strong positive reaction', '+++', 'Erythema, infiltration, confluent vesicles, bullae or ulceration', 'Extreme positive reaction', 'ir', 'Inflammation sharply limited to the exposed area, lack of infiltrate,', 'Irritant reaction', 'small petechiae, pustules, and efflorescences other than papules', 'and vesicles', 'Nt', 'Not tested', '8.', 'At the last reading, the investigator will provide an interpretation regarding a possible', 'sensitization reaction using the following scale:', 'Table 6', 'Suspected sensitization - conclusion']"
49,page_50,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 50 of 88', 'Sensitization Reaction', '0', 'Negative (absence of reaction or might be irritant reaction)', '1', 'Equivocal', '2', 'Positive', 'CCI', 'b) In case of suspicion of immediate contact skin reaction (such as urticaria)', 'A case-by-case approach will be applied and the procedure to follow will be discussed with the', 'Sponsor.', '7.2.2.2.5', 'Procedures for reporting pregnancies', 'Any pregnancy occurring during clinical trials, where the fetus could have been exposed to the', 'study drug, must be monitored until its outcome in order to ensure the complete collection of safety', 'data on GALDERMA R&D products.', 'If a subject becomes pregnant, the Investigator is to do the following:', '1.', 'Withdraw the subject from the clinical trial.', 'CCI']"
50,page_51,"['GALDERMA R&D', 'RD.06.SPR.118291 Protocol V02 04Jun2019', 'Page 51 of 88', '5.', 'At the outcome of the pregnancy, complete the Pregnancy Surveillance Form - Part II:', 'Course and Outcome of Pregnancy, as fully as possible. Inform the CSO by telephone, then', 'fax or scan and send by e-mail this pregnancy form to the CSO within 24 hours.', '6.', 'If the pregnancy leads to an abortion (voluntary, spontaneous or therapeutic), in-utero', 'death, or congenital anomaly, follow the procedure for declaration of an SAE', '(see Section 7.2.2.2.2).', '7.3', 'Other assessments', '7.3.1', 'Photographs', 'CCI']"
51,page_52,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 52 of 88', 'CCI', '7.3.2', ""Dermatology Life Quality Index (DLQI) / Children's Dermatology Life Quality"", 'Index (C-DLQI)', 'Dermatology Life Quality Index (cDLQI/DLQI) will be completed by the subject at the baseline', 'and week 12 and 24/early termination prior to any Investigator assessments to not impact the', ""subject's answers to the quality of life questionnaire. Subjects 16 years and younger (at baseline)"", 'should complete the cDLQI (and 17 years and older complete the DLQI) throughout the study.', 'Prior to any acne assessments, the Investigator or designee should provide the subject with the age', 'appropriate DLQI Form and instruct the subject to read and answer all 10 quality-of-life questions.', 'The designated study personnel will then check the questionnaire for completeness prior to', 'the subject leaving the office.', 'This QOL instrument is not acne specific. The DLQI/C-DLQI are validated instruments that', 'measure the dermatology-related limitations of functional ability and the frequency, severity, and', 'impact of general inflammatory skin conditions on the quality of life.', 'The six domains addressed in the questionnaire are:', 'symptoms and feelings;', 'daily activities;', 'leisure;', 'work/school;', 'personal relationships;', 'treatment.', 'The possible answers to the DLQI questions for the effect of acne on QOL were scored as', 'follows: very much (3), a lot (2), a little (1), and not at all (0). The DLQI is calculated by']"
52,page_53,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 53 of 88', 'summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. A', 'lower score on the DLQI indicated increased QOL; therefore, negative changes from Baseline', 'indicate improvement. The meaning of the DLQI total scores were interpreted as: no effect (0-1),', 'small effect (2-5), moderate effect (6-10), very large effect (11-20), or extremely large effect (21-', '30).', 'For the cDLQI:', 'The meaning of the DLQI total scores were interpreted as: no effect (0-1), small effect (2-6),', 'moderate effect (7-12), very large effect (13-18), or extremely large effect (19-30).', 'The higher the score, the more quality of life is impaired. For instructions of use and scoring:', ' http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-', 'instructions-for-use-and-scoring', 'The questionnaires completed will be considered as source data and the answers will be entered', 'into the CRF by the site.', '7.3.3', 'CompAQ for Facial and Truncal Acne', 'It will be collected at baseline, week 12 and 24/ early termination. The Investigator or designee', 'should provide the subject (16 years of age and older) with the comprehensive QoL measure', 'inclusive of facial and truncal form and instruct the subject to read and answer all 20 quality of life', 'questions. The questionnaire will measure the impact of facial and torso acne on health-related', 'quality of life.', 'The 20 questions consists of 5 domains that assess a variety of psychosocial and physical impacts', 'of acne: Psychological/Emotional, Social (Judgement From Others), Social Interactions,', 'Treatment Concerns, Physical Symptoms. The score on the CompAQ has a possible range of 0 to', '160. The higher the score, the more quality of life is impaired. For instructions of use and scoring', '(Chelsea McLellan, Marc P. Frey, Diane Thiboutot, Alison Layton, Mary-Margaret Chren, Jerry', 'Tan, Development of a Comprehensive Quality-of-Life Measure for Facial and Torso Acne.', 'Journal of Cutaneous Medicine and Surgery First Published January 31, 2018', 'https://doi.org/10.1177/1203475418756379)', 'An anchor question is added in order to detect responsivity with intervention and for Minimal', 'Clinically Important Difference (MCID).', 'Higher scores indicate greater adverse impact', 'The response range for each question is from 0-8 with higher numbers indicating greater adverse', 'impact.', 'For each domain, response range is from 0-32.', 'For the long form questionnaire, response range is from 0-160', 'For the short form questionnaire, response range is from 0-40', 'The investigator or delegate will then check all questions of the questionnaire for completeness', 'prior to the subject leaving the office.']"
53,page_54,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 54 of 88', '7.3.4', 'EuroQoL 5-Dimension (EQ-5D-5L)', 'At baseline and weeks 12 and 24/Early termination, subject will complete the EQ-5D-5L', '(Appendix 13.6).', 'EQ-5D-5L is a validated questionnaire for the assessment of the general health state. It contains', 'two parts: a descriptive system and a VAS. The descriptive system is made up of five dimensions:', 'mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The VAS consists of', 'a vertical line where the subject can assess his or her own health status. EQ-5D-5L will be', 'administered according to the schedule of assessments only to the subset of subjects who fluently', 'speak a language in which the questionnaire is presented (based on availability of validated', 'translations in participating countries).', '7.3.5', 'Subject satisfaction questionnaire', 'At weeks 12 and 24/Early termination, subject will complete a satisfaction questionnaire regarding', 'the investigational products they have been using in this trial (see Appendix 13.1). CCI', '7.3.6', 'Study drug acceptability questionnaire', 'At weeks 12 and 24/Early termination, subjects will complete an acceptability questionnaire', 'regarding use of the study drug (see Appendix 13.2).', '8', 'CLINICAL TRIAL VISITS DESCRIPTIONS AND PROCEDURES', '8.1', 'Description of clinical trial visits', 'Please refer to the Schedule of Assessments table in the Synopsis (Table 2).', 'A written, dated, initialed and signed ICF, Assent Form for minors, HIPAA, and Photo Consent', 'Form or Photo Assent form, must be obtained prior to performing any clinical trial-related', 'evaluations and/or procedures.', 'CCI']"
54,page_55,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 55 of 88']"
55,page_56,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 56 of 88', 'CCI']"
56,page_57,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 57 of 88']"
57,page_58,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 58 of 88']"
58,page_59,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 59 of 88']"
59,page_60,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 60 of 88']"
60,page_61,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 61 of 88', '8.1.9', 'Unscheduled visits', 'An unscheduled visit may occur for safety reasons.', 'During these visits, the assessments will be conducted as appropriate depending on the reason for', 'the visit.']"
61,page_62,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 62 of 88', 'CCI', '9', 'STATISTICAL METHODS PLANNED', '9.1', 'Statistical analysis plan', 'A statistical analysis plan (SAP) will be developed and issued as a separate document. The SAP', 'will contain a more detailed and technical description of specific data conventions, calculations', 'and of statistical procedures for executing the analysis strategies that are specified in the sections', 'of the clinical trial outline below. The SAP will be finalized prior to the database lock.', 'CCI', 'CCI', 'Any changes to analyses made after the SAP has been finalized, along with an explanation as to', 'when and why they occurred, will be documented in the clinical study report. Post hoc exploratory', 'analyses will also be clearly identified in the Clinical Study Report (CSR).', '9.1.1', 'Data transformations', 'Not applicable']"
62,page_63,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 63 of 88', '9.1.2', 'Populations analyzed, evaluability and limitation / evaluation of bias', 'The Intention-to-Treat (ITT) population will be used for the analyses of efficacy endpoints', 'CCI', 'CCI', '9.1.3', 'Data presentation and graphics', 'For statistical analyses purpose, baseline is defined as the last measurement prior to the first', 'application of the study drug and all analyses will be summarized by visits.', 'For the summary statistics, the categorical data will be summarized by frequency and percentage', 'of subjects for each response category (N, %) and the continuous data will be summarized using', 'number of subjects, mean, median, minimum, maximum, and standard deviation.']"
63,page_64,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 64 of 88', 'Subject disposition, demographics and baseline characteristics, previous therapies, and', 'concomitant therapies will be summarized by descriptive statistics based on the ITT Population.', 'Treatment exposure and compliance data will be summarized based on the Safety Population.', 'For statistical analysis purposes, previous therapies/procedures are defined as those ending at', 'Baseline or before; and concomitant therapies/procedures are defined as those ongoing at the', 'Baseline visit or starting after the Baseline visit.', 'Treatment-emergent Adverse Events (TEAEs) are defined as AEs with onset on or after first dose', 'of study drug; or those AEs with onset prior to first dose of study drug but worsened during', 'treatment.', 'TEAEs will be tabulated in frequency tables by System Organ Class (SOC) and Preferred Term', '(PT) based on the Medical Dictionary for Regulatory Activities (MedDRA). Additional summary', 'tables will be provided for SAEs, AEs considered related to the study drug, severe AEs, AESIs,', 'and AEs leading to discontinuation. For a given AE, a subject will be counted once even if he/she', 'has experienced multiple episodes of that particular AE.', 'In addition, non TEAEs will be summarized or listed separately.', 'For local tolerability (erythema, scaling, dryness, stinging/burning), data will be summarized for', 'worst score over treatment period, the final score during treatment, as well as scores for each visit.', 'The quality of life indices, EQ-5D-5L, COMPAQ (including the anchor question), C-DLQI, and', 'DLQI will be summarized descriptively.', 'Subgroup analyses will be explored by analysis center, age (<18 years, >18 years), gender and race', 'if appropriate for efficacy endpoint, and safety endpoints (TEAEs and Local tolerability).', 'Further details will be provided in the SAP.', '9.1.3.1', 'Imputation of missing data', 'The last observation carried forward (LOCF) will be used to impute efficacy endpoints, where', 'applicable. Non-responder analysis will also be carried out for Binary endpoints.', 'Further details will be provided in the SAP.', '9.1.3.2', 'Statistical hypothesis testing and multiplicity adjustment', 'Analysis of Efficacy Endpoint', 'All efficacy and patient reported endpoints will be summarized with point estimate and 95%', 'confidence intervals.', 'Further details will be provided in SAP.']"
64,page_65,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 65 of 88', '9.2', 'Sample size determination', 'There is no formal hypothesis to be tested. An estimation approach will be performed. Point', 'estimate and 95% confidence interval will constructed. Approximately 50 subjects will be enrolled', 'to evaluate the subject reported outcomes (quality of life and satisfaction survey).', '10', 'TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE', '10.1', 'Personnel training', 'Investigators training will occur on-site during the site initiation visit. It is recommended that all', 'investigators, other evaluators, study coordinators and other applicable personnel attend the site', 'initiation visit. During these meetings/trainings,', 'CCI', 'All sites must complete photography training and submit test photos of all required light conditions', 'CCI', 'The Investigators and study coordinators are expected to attend the Investigator receive on-site', 'training during the site initiation visit prior to participating in the procedures and evaluations in', 'this study. Each site will have a training record as part of the site file and Trial Master File. An', 'Investigator Site File will be provided to each study center.', 'A study initiation visit will be conducted for each study center prior to enrollment of any subjects.', 'CRAs and other applicable personnel will be trained prior to study initiation to familiarize CRAs', 'with the disease, the Standard Operating Procedures (SOP), the protocol and other study specific', 'items. Team organization, communication and operational issues will also be discussed.', '10.2', 'Clinical monitoring', 'The conduct of the clinical trial will be closely monitored by representatives of', 'GALDERMA R&D and/or Contract Research Organization (CRO) to verify adherence to the', 'clinical trial protocol, ICH-GCP guidelines, and applicable SOPs/study procedures.']"
65,page_66,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 66 of 88', ""The Investigator will allow the CRO /Sponsor's representatives, to have direct access to all clinical"", 'trial records, CRFs, corresponding subject medical records, study drug dispensing records, study', 'drug storage area, clinical trial facilities, and any other documents considered source', 'documentation.', 'The Investigator also agrees to assist the representative if required.', '10.3', 'Data management', 'The designated CRO will be responsible for activities associated with the data management of this', 'study.', 'This will include, but not limited to, setting up a relevant database and data transfer mechanisms,', 'along with appropriate validation of data and resolution of queries.', 'Study sites will enter data directly into an electronic data capture (EDC) system by completing the', 'CRF via a secure internet connection. Data entered into the CRF must be verifiable against source', 'documents at the study center. Data to be recorded directly on the CRF will be identified and the', 'CRF will be considered the source document. Any changes to the data entered into the EDC system', 'will be recorded in the audit trail.', 'All data management activities will be detailed in a Data Management Plan (DMP).', '10.4', 'Quality assurance / audit / inspection', 'The clinical trial is conducted under the sponsorship of GALDERMA R&D in compliance with', 'the applicable international and local regulatory requirements as well as applicable ICH guidelines', 'and in accordance with the SOPs for clinical trial conduct and monitoring from GALDERMA', 'and/or the CRO.', 'At the completion of the study, digital images will be forwarded to the Sponsor according to', 'individual testing facility SOPs.', 'Audits of clinical trial centers may be conducted by the Sponsor/CRO representatives, and', 'inspection may be performed by Regulatory Authority inspectorates or IRBs/IECs before, during,', 'or after the clinical trial.', ""The Investigator will allow and assist the CRO /Sponsor's representatives, IRBs/IECs and any"", 'regulatory agency to have direct access to all requested clinical trial-related records.', 'For the audits performed by, or on behalf of, GALDERMA auditors, audit certificate(s) will be', 'provided by Quality Assurance.', '10.5', 'Changes in clinical trial conduct / amendments']"
66,page_67,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 67 of 88', '10.5.1', 'Clinical trial conduct', 'With the exception of eliminating an immediate hazard to a subject, the Investigator should not', 'deviate from the clinical trial protocol or implement any changes without written approval from', 'the Sponsor and prior review and documented approval/favorable opinion from the IRB/IEC of a', 'protocol amendment.', 'Changes that involve only logistical or administrative changes to the clinical trial protocol are', 'authorized. The Investigator should document and explain any deviation from the clinical trial', 'protocol.', '10.5.2', 'Amendments', 'The Sponsor may modify the clinical trial protocol at any time for ethical, medical, or scientific', 'reasons.', '10.5.3', 'Attrition', 'Clinical studies may experience attrition. Subjects will be made aware that they are free to', 'withdraw from the study at any time for any reason, without prejudice. Otherwise, every effort will', 'be made to have subjects complete the study as stated in this protocol, ensuring subject safety and', 'following the provisions of the ICF. Reasons for subject withdrawal may include an AE, SAE,', ""subject's request, protocol violation, lost to follow-up, and other reasons. Subjects lost from the"", 'study will be documented on a screening/enrollment log.', 'If a subject fails to return for a scheduled examination, a representative of clinical site (site', 'representative/study coordinator) will attempt to contact the subject and determine whether the', 'subject has continued to follow study instructions and intends to continue participation in the study.', 'If so, then the subject will be rescheduled to come into the clinic as soon as possible.', 'If a rescheduled visit is outside of the specified time frame window, this will be recorded in the', 'screening/enrollment log and as a deviation.', 'If a subject cannot reschedule in an acceptable time frame and completely misses 1 study visit, the', 'subject may be allowed to continue study participation at the discretion of the Investigator and the', 'Sponsor, provided that the subject has continued to comply with study instructions. If the subject', 'is allowed to continue, the missed visit will be noted in the screening/enrollment log and recorded', 'as a protocol deviation. Subjects will not be allowed to miss the week 12 visit.', '11', 'ETHICS AND GENERAL CLINICAL TRIAL CONDUCT CONSIDERATIONS']"
67,page_68,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 68 of 88', '11.1', 'Institutional Review Board or Independent Ethics Committee', 'This study (protocol, ICF and all addenda) will be reviewed and approved by IntegReview IRB.', 'The study will not be activated and subjects will not be consented, receive any study products, or', 'participate in any study procedures until such time as the IRB has approved the protocol and the', 'ICF. In addition, the IRB will review the study before any significant change in the protocol is', ""initiated. After each review, the IRB's approval will be documented in a letter to the Investigator"", 'and a copy of the IRB approval letter will be forwarded to the Sponsor.', '11.2', 'Ethical conduct of the clinical trial', 'This clinical trial will be conducted in accordance with the protocol, the HELSINKI declaration', '(1964) and subsequent amendments, and the ICH GCP, and in compliance with applicable', 'regulatory requirements.', '11.3', 'Subject information and consent', 'All subjects who participate in this clinical trial are required to be fully informed about the clinical', 'trial in accordance with GCPs guidelines, federal regulations, HIPAA (if in the US), or applicable', 'local privacy act if in other countries, and guidelines and in accordance with local requirements.', 'The ICF, Assent Form, HIPAA or other applicable local privacy act), and Photo Consent Form,', 'approved by an IRB/IEC, will be fully explained to the subject.', ""Prior to enrolment into the clinical trial, the subject and as needed, the subject's parent/legal"", 'representative will sign and date the consent form(s), including assent. The Investigator is', ""responsible for maintaining each subject's consent form(s) in the Investigator's site file and"", 'providing each subject, and his/her parent legal representative with a copy of the signed and dated', 'consent form(s) including assent.', '11.4', 'Contractual requirements', 'A', 'contractual agreement will be signed between the Sponsor/CRO and each', 'Investigator/Institution. This document will contain supplementary information, including', 'financial terms, confidentiality, the clinical trial schedule, third party responsibility, and', 'publication rights.', '11.5', 'Data collection and archiving', '11.5.1', 'Data collection']"
68,page_69,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 69 of 88', 'The Investigator must maintain all required records for all subjects. Data for this clinical trial will', ""be recorded in the subject's source documents, subject photographs and on the CRFs provided by"", 'the Sponsor. All data should be recorded on the CRFs completely and promptly.', '11.5.2', 'Source documentation', 'The Investigator must keep accurate separate records (other than the CRFs) of all subject visits,', 'being sure to include all pertinent clinical trial-related information. A statement should be made', 'indicating that the subjects have been included in this clinical trial and have provided signed', 'written Informed Consent and Assent as applicable. All AEs must be thoroughly documented.', 'Results of any diagnostic tests conducted during the clinical trial should also be included in the', 'source documentation.', '11.5.3', 'Archives', 'All pertinent data, samples, photographs, correspondence, and reports, the original or amended', 'clinical trial protocol, and all other material relating to the clinical trial will be maintained securely', 'in Sponsor/CRO Investigator/Institution archives for the legally required duration for archiving.', 'The Investigator/Institution should maintain the essential clinical trial documents as specified in', 'Section 8 of ICH-GCP, and according to the applicable regulatory requirements.', 'The Investigator/Institution should take measures to prevent accidental or premature destruction', 'of these documents.', 'If the Principal Investigator retires, relocates, or withdraws from the responsibility of keeping the', 'clinical trial records for any other reasons, custody must be transferred to a person who will accept', 'the responsibility. The Sponsor/CRO must be notified in writing of the name and address of the', 'new custodian.', '11.6', 'Insurance', 'A certificate attesting Third Party coverage of Sponsor/CRO will be provided upon request.', '12', 'LITERATURE REFERENCE LIST', '1. Canavan TN, Chen E, Elewski BE. Optimizing non-antibiotic treatments for patients with', 'acne: a review. Dermatol Ther. 2016;6(4):1-24.', '2. Tsatsou F, Zouboulis CC. Anatomy of the sebaceous gland. In: Zouboulis C, Katsambas', 'A, Kligman, A, eds. Pathogenesis and Treatment of Acne and Rosacea. London, UK:', 'Springer; 2014:27-31.']"
69,page_70,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 70 of 88', '3. Koo JY, et al. Psychologic aspects of acne. Pediatr Dermatol. 1991; 8:185-8.', '4. Osterweil N, ed. Frustrated adults told acne was adolescent disease, survey says. Dermatol', 'Times. 1993;14(suppl):S5-S6.', '5. Bayramgurler D, Pelin Kartal S, Altunel, C. Use of topical retinoids in acne. In: Pelin', 'Kartal, ed.Acne and Acneiform Eruptions. London, UK: IntechOpen; 2017: 118-127.', '6. Dreno B. Pathophysiology of acne. Presse Medicale. 2005 Apr 9;34(7):537-9.', '7. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment.', '2003;63(15):1579-1596.', '8. Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment.', 'Cutis. 2006 May;77(5):285-9.', '9. Joseph Bikowski. Managing Two Challenging Presentations of Acne. Practical', 'Dermatology, March 2011 : 63-65', '10. Del Rosso JQ, Bikowski JB, Baum E, Smith J, Hawkes S, Benes V, Bhatia N. A closer', 'look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs', 'Dermatol. 2007 Jun;6(6):597-600.', '11. Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, et al.', 'Structure-based design of Trifarotene (CD5789), a potent and selective RARgamma', 'agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;28(10):1736-41.', '12. Del Rosso JQ. The role of skin care as an integral component in the management of acne', 'vulgaris: Part 1: The importance of cleanser and moisturizer ingredients, design, and', 'product selection. J Clin Aesthet Dermatol. 2013;6(12):19-27.', '13. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical', 'manifestations, and management strategies. Jour Clin Aesthet Dermatol., 2010 Apr;', '3(4):24-38.', '14. Schorr ES, Sidou F, Kerrouche N. Adjunctive use of a facial moisturizer SPF 30 containing', 'ceramide precursor improves tolerability of topical tretinoin 0.05%: a randomized,', 'investigator-blinded, split-face study. J Drugs Dermatol. 2012;11(9):1104-1107.', '15. Bowe WP, Kircik LH. Importance of photoprotection and moisturization in treating acne', 'vulgaris J Drugs Dermatol. 2014 Aug; 13(8): s89-94.', '16. Del Rosso JQ, Brandt S. The role of skin care as an integral component in the management', 'of acne vulgaris. Part 2: Tolerability and performance of a designated skin care regimen', 'using a foam wash and moisturizer SPF 30 in patients with acne vulgaris undergoing active', 'treatment. J Clin Aesthet Dermatol. 2013;6(12):28-36', '17. Usatine R, Quan M, Strick R. Acne vulgaris:a treatment update. Hosp Prac 1998;Feb', '15:111-127.', '18. Pawin H., Beylot C., Chivot M. et al., Physiopathology of acne vulgaris: recent data, new', 'understanding of the treatments. Eur J Dermatol. 2004 Jan Feb;14(1):4 12.']"
70,page_71,"['GALDERMA R&D', 'RD.06.SPR.118291 Protocol V02 04Jun2019', 'Page 71 of 88', '19. Leyden J.J. Topical treatment of acne vulgaris: Retinoids and cutaneous irritation. J Am', 'Acad Dermatol. 1998 Apr; 38(4):S1 4.', '20. Rizer, RL, Mills, OH, Trookman, NS. The assessment of acne: a re-evaluation of grading', 'strategies. Scientific Poster, Annual Meeting of the American Academy of Dermatology', '(2001).', '21. Dreno B, Bissonnette R, Gagne-Henley A, et al. Prevention and Reduction of Atrophic Acne Scars', 'with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial', 'Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual', 'Comparison. Am J Clin Dermatol. 2018;19(2):275-286.', '22. Cook CH, Centner RC, Michaels SE. An acne grading method using photographic', 'standards. Arch Dermatol. 1979;115:571-575.']"
71,page_72,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 72 of 88']"
72,page_73,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 73 of 88', 'CCI']"
73,page_74,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 74 of 88', 'CCI']"
74,page_75,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 75 of 88', '13.3', 'Dermatology Life Quality Index (DLQIT)', 'The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE', 'LAST WEEK. Please tick one box for each question.', '1.', 'Over the last week, how itchy, sore,', 'Very much', 'painful or stinging has your skin', 'A lot', 'been?', 'A little', 'Not at all', '2.', 'Over the last week, how embarrassed', 'Very much', 'or self-conscious have you been because', 'A lot', 'of your skin?', 'A little', 'Not at all', '3.', 'Over the last week, how much has your', 'Very much', 'skin interfered with you going', 'A lot', 'shopping or looking after your home or', 'A little', 'garden?', 'Not at all', 'Not relevant', '4.', 'Over the last week, how much has your', 'Very much', 'skin influenced the clothes', 'A lot', 'you wear?', 'A little', 'Not at all', 'Not relevant', '5.', 'Over the last week, how much has your', 'Very much', 'skin affected any social or', 'A lot', 'leisure activities?', 'A little', 'Not at all', 'Not relevant', '6.', 'Over the last week, how much has your', 'Very much', 'skin made it difficult for', 'A lot', 'you to do any sport?', 'A little', 'Not at all', 'Not relevant', '7.', 'Over the last week, has your skin prevented', 'Yes', 'you from working or studying?', 'No', 'Not relevant', 'If ""No"", over the last week how much has', 'A lot', 'your skin been a problem at', 'A little', 'work or studying?', 'Not at all', '8.', 'Over the last week, how much has your', 'Very much', 'skin created problems with your', 'A lot', 'partner or any of your close friends', 'A little', 'or relatives?', 'Not at all', 'Not relevant']"
75,page_76,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 76 of 88', '9.', 'Over the last week, how much has your', 'Very much', 'skin caused any sexual difficulties?', 'A lot', 'A little', 'Not at all', 'Not relevant', '10.', 'Over the last week, how much of a', 'Very much', 'problem has the treatment for your', 'A lot', 'skin been, for example by making', 'A little', 'your home messy, or by taking up time?', 'Not at all', 'Not relevant', 'Please check that you have answered EVERY question. Thank you.', 'AY Finlay, GK Khan, April 1992, This must not be copied without the permission of the authors.']"
76,page_77,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 77 of 88', '13.4', ""Children's Dermatology Life Quality Index (C-DLQITM)"", 'The aim of this questionnaire is to measure how much your skin problem has affected you OVER THE LAST', 'WEEK. Please tick one box for each question.', '1.', 'Over the last week, how itchy, ""scratchy"",', 'Very much', 'sore or painful has your skin been?', 'Quite a lot', 'Only a little', 'Not at all', '2.', 'Over the last week, how embarrassed', 'Very much', 'or self conscious, upset or sad have you', 'Quite a lot', 'been because of your skin?', 'Only a little', 'Not at all', '3.', 'Over the last week, how much has your', 'Very much', 'skin affected your friendships?', 'Quite a lot', 'Only a little', 'Not at all', '4.', 'Over the last week, how much have you changed', 'Very much', 'or worn different or special clothes/shoes', 'Quite a lot', 'because of your skin?', 'Only a little', 'Not at all', '5.', 'Over the last week, how much has your', 'Very much', 'skin trouble affected going out, playing,', 'Quite a lot', 'or doing hobbies?', 'Only a little', 'Not at all', '6.', 'Over the last week, how much have you', 'Very much', 'avoided swimming or other sports because', 'Quite a lot', 'of your skin trouble?', 'Only a little', 'Not at all', '7.', 'Last week,', 'If school time: Over the', 'Prevented school', 'was it', 'last week, how much did', 'Very much', 'school time?', 'your skin affect your', 'Quite a lot', 'school work?', 'Only a little', 'OR', 'Not at all', 'was it', 'If holiday time: How much', 'Very much', 'holiday time?', 'over the last week, has your', 'Quite a lot', 'skin problem interfered with', 'Only a little', 'your enjoyment of the holiday?', 'Not at all', '8.', 'Over the last week, how much trouble', 'Very much', 'have you had because of your skin with', 'Quite a lot', 'other people calling you names, teasing,', 'Only a little', 'bullying, asking questions or avoiding you?', 'Not at all']"
77,page_78,"['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 78 of 88', '9.', 'Over the last week, how much has your sleep', 'Very much', 'been affected by your skin problem?', 'Quite a lot', 'Only a little', 'Not at all', '10.', 'Over the last week, how much of a', 'Very much', 'problem has the treatment for your', 'Quite a lot', 'skin been?', 'Only a little', 'Not at all', 'Please check that you have answered EVERY question. Thank you.', 'M.S. Lewis-Jones, A.Y. Finlay, May 1993, This must not be copied without the permission of the authors.']"
78,page_79,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 79 of 88', '13.5', 'QOL Questionnaire for Face and Trunk Acne (16 years of age and older)', 'CompAQ Measure (Long Form)', 'We define acne as pimples, zits, or breakouts. We do not mean holes, dark spots, or red spots left', 'by acne.', 'Thinking about the last 7 days, please answer the following questions about acne on your', '[face/torso (eg, chest, back, shoulders)] using the following scale:', '0', '1', '2', '3', '4', '5', '6', '7', '8', 'Never', 'Rarely', 'Sometimes', 'Often', 'All the time', 'Items, split by domain', 'Response Choices', '0', '1', '2', '3', '4', '5', '6', '7', '8', 'A. Psychological/Emotional', 'Because of my acne', '1.', 'I feel depressed, sad, or upset.', '2. I feel embarrassed.', '3. I feel self-conscious.', '4.', 'I feel less confident.', 'B. Social (Judgment from others)', 'Because of my acne', '5.', 'I feel that people stare at me.', '6.', 'I feel like people judge me.', '7. People treat me differently.', '8. People think less of me.', 'C. Social Interactions', 'Because of my acne', '9. I avoid social interactions.', '10. I spend less time with my friends.', '11. I am concerned about meeting new people.', '12. I am uncomfortable showing affection to others.', 'D. Treatment Concerns', 'Because of my acne', '13. I spend a lot time taking care of my skin (at home remedies,', 'treatments, cleansing).', '14. I spend time looking at my skin.', '15. I am concerned that my skin will never be clear.', '16. I am concerned about side effects from treatment.', 'E. Physical Symptoms', 'Because of my acne']"
79,page_80,"['GALDERMA R&D', 'RD.06.SPR.11829 Protocol V02 04Jun2019', 'Page 80 of 88', '17. My skin feels bumpy or uneven.', '18. My skin feels dirty.', '19. My skin is red.', '20. My skin causes me discomfort or pain.', 'Since your baseline visit in this study, has there been any change in overall quality of life', 'related to your acne?', 'RESPONSE RANGE:', 'Patient instructions: Please circle the number that best describes your response where -7 indicates', 'a great deal WORSE and +7 indicates a great deal BETTER', '-7', '(a great deal WORSE) -6 -5 -4 -3 -2 -1 0 (No change) +1', '+2', '+3', '+4', '+5', '+6 +7 (a great deal BETTER)', 'The above is based on this section of the paper for MCID determination for DLQI GRCQ', 'The GRCQ [4], used as an anchor, allows patients to give a self-assessment of the change since', 'baseline assessment in, for example, overall QoL or severity of skin condition, whether it has', 'improved, remained the same or deteriorated. It has a 15-point scoring system with responses', 'ranging from a very great deal better (+7) to no change (0) to a very great deal worse (-7). The', 'GRCQ with a 15-point scoring system was chosen to maximize the sensitivity of the responses.', 'Respondents with scores of 0, - 1 or 1 are classified as unchanged or having a small but unimportant', 'change. Respondents whose scores are 2, 3, -2 or -3 are considered to have experienced a small', 'change equivalent to the minimal important difference. Those with scores of 4, 5, -4 or -5 are', 'considered to have experienced a moderate change, and those with scores of 6, 7, -6 or -7 are', 'considered to have experienced a large change [3,4]. The question posed was: ""Since your first', ""clinic visit, has there been any change in overall quality of life related to your skin disease?'"", 'REF: Basra M, K, A, Salek M, S, Camilleri L, Sturkey R, Finlay A, Y: Determining the Minimal', 'Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index', '(DLQI): Further Data. Dermatology 2015;230:27-33. doi: 10.1159/000365390']"
80,page_81,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 81 of 88', '13.6', 'EuroQoL 5-Dimension (EQ-5D-5L)', 'EuroQoL 5- Dimension (EQ-5D-5L)', 'Under each heading, please check the ONE box that best describes your health TODAY.', 'MOBILITY', 'I have no problems walking', 'I have slight problems walking', 'I have moderate problems walking', 'I have severe problems walking', 'I am unable to walk', 'SELF-CARE', 'I have no problems washing or dressing myself', 'I have slight problems washing or dressing myself', 'I have moderate problems washing or dressing myself', 'I have severe problems washing or dressing myself', 'I am unable to wash or dress myself', 'USUAL ACTIVITIES (e.g. work, study, housework, family or leisure', 'activities)', 'I have no problems doing my usual activities', 'I have slight problems doing my usual activities', 'I have moderate problems doing my usual activities', 'I have severe problems doing my usual activities', 'I am unable to do my usual activities', 'PAIN / DISCOMFORT', 'I have no pain or discomfort', 'I have slight pain or discomfort', 'I have moderate pain or discomfort', 'I have severe pain or discomfort', 'I have extreme pain or discomfort', 'ANXIETY / DEPRESSION', 'I am not anxious or depressed', 'I am slightly anxious or depressed', 'I am moderately anxious or depressed', 'I am severely anxious or depressed', 'I am extremely anxious or depressed']"
81,page_82,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 82 of 88', 'We would like to know how good or bad your health is TODAY', 'The best health', 'you can imagine', 'This scale is numbered from 0 to 100.', '100', '95', '100 means the best health you can imagine.', '0 means the worst health you can imagine.', '90', 'Mark an X on the scale to indicate how your health is TODAY', '85', 'Now, please write the number you marked on the scale in the box', '80', 'below.', '75', '70', '65', '60', '55', '50', 'YOUR HEALTH TODAY =', '45', '40', '35', '30', '25', '20', '15', '10', '5', '0', 'The worst health', 'you can imagine']"
82,page_83,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 83 of 88', '13.7', 'Fitzpatrick Skin Classification', ""The Fitzpatrick skin classification is based on the skin's unprotected response to the first 30 to 45"", 'minutes of sun exposure after a winter season without sun exposure. The categories of skin types', 'are as follows:', 'I', 'White; very fair; red or blonde hair; blue eyes; freckles', 'Always burns easily; never tans', 'II', 'White; fair; red or blonde hair; blue, hazel, or green eyes', 'Always burns easily; tans minimally', 'III', 'Cream white; fair with any eye or hair color; very common', 'Burns moderately; tans gradually', 'IV', 'Brown; typical Mediterranean white skin', 'Burns minimally; always tans well', 'V', 'Dark brown; mid-eastern skin types, black hair, olive skin', 'Rarely burns; tans profusely', 'VI', 'Black; black hair, black eyes, black skin', 'Never burns; deeply pigmented']"
83,page_84,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 84 of 88', 'CCI']"
84,page_85,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 85 of 88']"
85,page_86,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 86 of 88', 'CCI']"
86,page_87,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 87 of 88']"
87,page_88,"['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 88 of 88', 'Protocol Signature Page', 'I agree to conduct the trial in compliance:', 'With the protocol, or any applicable amendment(s), agreed to by the sponsor, regulatory', 'authority and which was given a favorable opinion by the IRB/IEC', 'With Good Clinical Practices', 'With applicable local and international laws and regulations', 'With the instructions I received about', '- ethic principles and subjects protection', '- data collection and reporting', '- study drug(s) and material(s) use and management', '- clinical trial monitoring, audit and inspection', 'I have read this protocol in its entirety, including the above statement, and I agree to all aspects.', 'Investigator (first name/last name)', 'Signature', 'Date:']"
